Liquidia (LQDA) Free Cash Flow Growth (3y) (2023 - 2026)
Liquidia (LQDA) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 14.41% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 216.31% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 4.08% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 49.44% |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -10.40% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -9.38% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 134.18% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Liquidia | 6.38 Bn | 6.10 Bn | 160.92 Mn | 144.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 144.02% |
| Mar 31, 2026 | 93.63% |
| Dec 31, 2025 | 120.32% |
| Sep 30, 2025 | -22.10% |
| Jun 30, 2025 | -62.54% |
| Mar 31, 2025 | -53.41% |
| Dec 31, 2024 | -31.82% |
| Sep 30, 2024 | -68.93% |
| Jun 30, 2024 | -38.98% |
| Mar 31, 2024 | -27.60% |
| Dec 31, 2023 | -5.72% |
| Sep 30, 2023 | 2.31% |
| Jun 30, 2023 | 23.76% |
| Mar 31, 2023 | 15.15% |